Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation
Phytomedicine · 2024-07 · 130 · 155774
DOI: 10.1016/j.phymed.2024.155774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2024-07. Verfasst von Dan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China; H…. Hauptthemen laut MEDLINE: Chrysanthemum, Gastrointestinal Microbiome, PPAR gamma, PPAR alpha. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Metabolic and alcohol-associated liver disease (MetALD) shows a high prevalence rate in liver patients, but there is currently no effective treatment for MetALD. As a typical edible traditional Chinese medicinal herb, the anti-inflammatory, antioxidant, and hepatoprotective properties of water extract of Chrysanthemum morifolium Ramat. (WECM) has been demonstrated. However, its therapeutic effect on MetALD and the associated mechanisms remain unclear. PURPOSE: To investigate the underlying mechanisms of WECM against MetALD. METHODS: We constructed a MetALD rat model following a high-fat & high-sucrose plus alcohol diet (HFHSAD). MetALD rats were treated with WECM at 2.1, 4.2, and 8.4 g/kg/d for six weeks. Efficacy was determined, and pathways associated with WECM against MetALD were predicted through serum and hepatic biochemical marker measurement, histopathological section analysis, 16S rDNA sequencing of the gut microbiota and untargeted serum metabolomics analyses. Changes in genes and proteins in the peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ) signaling pathways were detected by RT‒PCR and Western blotting. RESULTS: WECM treatment significantly attenuated hepatic steatosis, hyperlipidemia and markers of liver injury in MetALD rats. Moreover, WECM improved vascular endothelial function, hypertension, and systematic oxidative stress. Mechanistically, WECM treatment altered the overall structure of the gut microbiota through maintaining Firmicutes/Bacteroidota ratio and reducing harmful bacterial abundances such as Clostridium, Faecalibaculum, and Herminiimonas. Notably, WECM promoted 15-deoxy-△12, 14-prostaglandin J2 (15d-PGJ2) release and further activated the PPARγ to reduce serum TNF-α, IL-1β, and IL-6 levels. Additionally, WECM upregulated PPARα and downregulated the levels of CD36 and FABP4 to improve lipid metabolism. CONCLUSION: Our findings provide the first evidence that WECM treatment significantly improved hepatic steatosis, oxidative stress and inflammation in MetALD rats by regulating the gut microbiota and activating the 15d-PGJ2/PPARγ and PPARα signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China; Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan 4…
- Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
- School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan 430074, China.
- Key Laboratory of Chinese Medicine Quality Control of State Drug Administration, Hubei Institute for Drug Control, Wuhan 430075, China.
- Hubei Center for ADR Monitoring, Wuhan 430071, China.
Zitieren
APA
Liu, D., Zhan, J., Wang, S., Chen, L., Zhu, Q., Nie, R., Zhou, X., Zheng, W., Luo, X., Wang, B., Nie, J., & Ye, X. (2024). Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation. Phytomedicine, 130, 155774. https://doi.org/10.1016/j.phymed.2024.155774
Vancouver
Liu D, Zhan J, Wang S, Chen L, Zhu Q, Nie R, et al. Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation. Phytomedicine. 2024;130:155774. doi:10.1016/j.phymed.2024.155774
BibTeX
@article{Liu2024,
author = {Liu, Dan and Zhan, Jianting and Wang, Shiqin and Chen, Lvyi and Zhu, Qianqian and Nie, Ruili and Zhou, Xuxiang and Zheng, Wuyinxiao and Luo, Xin and Wang, Bo and Nie, Jing and Ye, Xiaochuan},
title = {Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation},
journal = {Phytomedicine},
year = {2024},
volume = {130},
pages = {155774},
doi = {10.1016/j.phymed.2024.155774}
}
EUVIMED